DOCSLIB.ORG

Filling in the Evidence About Sunscreen Robert M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Filling in the Evidence About Sunscreen Robert M Opinion EDITORIAL Filling in the Evidence About Sunscreen Robert M. Califf, MD; Kanade Shinkai, MD, PhD Skin cancer is the most common malignancy in the United through day 7 for all products except the cream. The concen- States and is estimated to affect more than 3.3 million indi- tration increased from day 1 to day 4, raising the suggestion viduals each year.1 Photoprotection, including sunscreen use of drug accumulation. Application of products with oxyben- for areas of skin not covered zone and octocrylene resulted in similar exposures, with by sun protective clothing or concentrations exceeding 0.5 ng/mL, demonstrating rising Related article shade, aims to reduce expo- plasma concentrations with ongoing use—consistent with sure to UV radiation, likely drug accumulation—as well as persistent systemic levels the main risk factor for the development of skin cancer. after discontinuing the sunscreen use, suggesting an Sunscreens were initially approved as over-the-counter extended half-life. Among the 6 participants using the cream (OTC) medications—indicated for the prevention of sunburn— (the only product with ecamsule), 5 had ecamsule concen- before the modern era of drug evaluation. Current understand- trations exceeding 0.5 ng/mL on day 1. Notably, post hoc ing of UV-related carcinogenesis supports the additional analysis demonstrated that almost all study participants had indication regarding use of sunscreen for the prevention of systemic levels exceeding the FDA threshold after a single skin cancer. However, because biological rationale has so day of sunscreen application. often proven to be misleading, drug manufacturers must dem- The demonstration of systemic absorption well above onstrate through empirical research in humans that benefits the FDA guideline does not mean these ingredients are outweigh risks for an intended use of a product in a specified unsafe. However, the study findings raise many important population. Has sunscreen met these current requirements questions about sunscreen and the process by which the for safety and effectiveness? sunscreen industry, clinicians, specialty organizations, and Concerns have been raised about the safety and effects of regulatory agencies evaluate the benefits and risks of this chemical sunscreens on endocrine, reproductive, develop- topical OTC medication. First and foremost, it is essential to mental, and cancer-related outcomes, as well as environmen- determine whether systemic absorption of sunscreen poses tal harm.2,3 Evidence that sunscreen may be systemically risks to human health. Second, the effects of different sun- absorbed was indicated by studies in humans as early screen formulations, clinical characteristics (ie, skin type, as 19974; in 2008, the Centers for Disease Control and Preven- age, presence of skin diseases that disrupt the skin barrier), tion demonstrated the presence of the common sunscreen physical activity level, and exposure to sun and water on ingredient oxybenzone in 97% of urine samples collected as systemic sunscreen levels require further study. An urgent part of the National Health and Nutrition Examination Survey.5 question involves absorption in infants and children, who However, there is a paucity of careful and systematic study have different ratios of body surface area to overall size and of a fundamental aspect of drug development: measurement whose skin may absorb substances at differential rates. of blood levels of active sunscreen ingredients over time when Understanding whether systemic levels result from means the product is used as directed. other than transdermal absorption, such as through inhala- The study by Matta et al6 in this issue of JAMA reports tion of spray sunscreen formulations, or from other sources findings from an open-label, randomized, 4-group pilot of these chemicals, including cosmetic products and indus- study in 24 adults to determine the systemic absorption and trial sources, also warrants clarification. In addition, testing pharmacokinetics of the sunscreen ingredients avobenzone, under actual use conditions will be paramount, as most oxybenzone, octocrylene, and ecamsule during maximum users apply less sunscreen than the recommended amount, sunscreen use. The study protocol required application often without reapplication.8 Although applying less sun- (2 mg/cm2) 4 times a day to 75% of body surface area for screen theoretically reduces safety concerns, whether 4 days. Each intervention group received a different combi- a lower dose also diminishes the putative benefits of nation of active sunscreen ingredients within commercially sunscreen is not known. available cream, lotion, or spray formulations. The sunscreen ingredients examined by Matta et al are The authors found evidence of measurable systemic found in the most commonly accessible formulations avail- absorption of all 4 sunscreen ingredients at levels meeting able in the United States and were applied at recommended the US Food and Drug Administration (FDA) guidelines to amounts and intervals consistent with current sunscreen trigger a requirement for further systemic safety testing.7 labeling. Sunscreen users reasonably presume that compa- Specifically, all 4 sunscreen products containing avobenzone nies that manufacture and sell sunscreens have conducted resulted in plasma concentrations above 0.5 ng/mL. These basic studies to support the safety and effectiveness of their levels were evident on day 1 with all products and lasted products and that the medical profession would demand jama.com (Reprinted) JAMA Published online May 6, 2019 E1 © 2019 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ by John Albertini on 05/27/2019 Opinion Editorial high-quality evidence. However, sunscreens have not been removal of sunscreen formulations containing these subjected to standard drug safety testing, and clinicians and ingredients from the US market. However, these deadlines consumers lack data on systemic drug levels despite decades can be extended if manufacturers commit to undertake the of widespread use. Furthermore, appropriately designed needed studies. trials have not yet been conducted to understand the opti- New sunscreen UV filters will require similar systemic mal sunscreen dose needed to achieve a balance of risk and safety studies, if these agents are significantly absorbed. benefit when used to prevent skin cancer and melanoma. Many sunscreen ingredients requiring additional testing The paucity of pharmacologic and clinical outcome evi- (and some awaiting approval) are critical to broad-spectrum dence is multifactorial. Despite multiple efforts by the FDA formulations—providing protection from UVA1 light in to persuade sunscreen manufacturers to conduct key safety particular—another requirement under the FDA monograph. studies, the manufacturers have failed to produce such data, Mineral sunscreens are less effective at meeting this forcing the FDA to conduct its own studies.9 In 2014, a pub- requirement unless used at high concentrations, which lic advisory panel convened by the FDA concluded that often results in cosmetically noticeable whitening of insufficient evidence existed to confirm the safety of many the skin. sunscreen ingredients and formulations.10 The panel also The findings of the study by Matta et al will likely raise concluded that high-quality evidence existed to demon- concerns in the medical community, as well as among strate prevention of sunburn, precancerous actinic keratosis, sunscreen users. Until more information is available, it and squamous cell cancer through sunscreen use but that will be important to continue to reinforce clinical evidence for melanoma prevention was not high quality. The recommendations15 regarding the beneficial effects of panel recommended specific information to allow older sun- photoprotection for skin cancer prevention that are rooted screen ingredients to remain on the market or to permit new in strong biological rationale and modest clinical evidence. ingredients to be marketed. The need for long-term safety Avoidance of the sunscreen ingredients highlighted in this data, as well as the challenges of performing effectiveness study, or of sunscreen altogether, could have significant studies on a population level, were acknowledged. negative health implications. At a minimum, physicians Delay in generating high-quality evidence is also rooted should recommend use of sunscreen formulations contain- in the regulatory history of sunscreen.11,12 Although regu- ing GRASE ingredients such as titanium dioxide and zinc lated as cosmetics throughout much of the world, sun- oxide as part of a larger program of photoprotection that screens in the United States have been subject to the FDA includes seeking shade, and wearing protective clothing, monograph system that evaluates OTC drug safety and effec- hats, and sunglasses, until meaningful answers to these tiveness. Multiple efforts to modernize this iterative system questions are available. to enable more rapid incorporation of evidence-based Understanding the effectiveness and safety of sunscreen changes have been unsuccessful. In 2014, Congress passed the ingredients will require a collaborative effort by industry, cli- Sunscreen Innovation Act to expedite entry of sunscreens nicians, and scientists. The power of collaboration is exem- available worldwide to the United States through an alterna- plified by the significant influence of the pharmaceutical tive FDA process while maintaining
Load more

Recommended publications
  • FDA Proposes Sunscreen Regulation Changes February 2019
    FDA Proposes Sunscreen Regulation Changes February 2019 The U.S. Food and Drug Administration (FDA) regulates sunscreens to ensure they meet safety and eectiveness standards. To improve the quality, safety, and eectiveness of sunscreens, FDA issued a proposed rule that describes updated proposed requirements for sunscreens. Given the recognized public health benets of sunscreen use, Americans should continue to use broad spectrum sunscreen with SPF 15 or higher with other sun protective measures as this important rulemaking eort moves forward. Highlights of FDA’s Proposals Sunscreen active ingredient safety and eectiveness Two ingredients (zinc oxide and titanium dioxide) are proposed to be safe and eective for sunscreen use and two (aminobenzoic acid (PABA) and trolamine salicylate) are 1 proposed as not safe and eective for sunscreen use. FDA proposes that it needs more safety information for the remaining 12 sunscreen ingredients (cinoxate, dioxybenzone, ensulizole, homosalate, meradimate, octinoxate, octisalate, octocrylene, padimate O, sulisobenzone, oxybenzone, avobenzone). New proposed sun protection factor Sunscreen dosage forms (SPF) and broad spectrum Sunscreen sprays, oils, lotions, creams, gels, butters, pastes, ointments, and sticks are requirements 2 proposed as safe and eective. FDA 3 • Raise the maximum proposed labeled SPF proposes that it needs more data for from SPF 50+ to SPF 60+ sunscreen powders. • Require any sunscreen SPF 15 or higher to be broad spectrum • Require for all broad spectrum products SPF 15 and above, as SPF increases, broad spectrum protection increases New proposed label requirements • Include alphabetical listing of active ingredients on the front panel • Require sunscreens with SPF below 15 to include “See Skin Cancer/Skin Aging alert” on the front panel 4 • Require font and placement changes to ensure SPF, broad spectrum, and water resistance statements stand out Sunscreen-insect repellent combination 5 products proposed not safe and eective www.fda.gov.
    [Show full text]
  • Chemical UVR Absorbers
    Chemical UVR Absorbers The names given in bold and used Diisopropyl methyl cinnamate Glyceryl ethyihexanoate dimethoxy- throughout this handbook are those of Empirical formula: cinnamate the International Nomenclature of C 6H22O2 Chemical names. Cosmetic Ingredients. Glyceryl octanoate dimethoxycinnamate; Chemical names: 2-propenoic acid, 3-(4-methoxyphenyl)-, 2-Propenoic acid, 3-12,4bis(1 diester with 1 ,3-dihydroxy-2-(2-ethyl-1 - methylethyphenyl-methyl ester; 2,5- oxohexyl)oxypropane diisopropyl methyl cinnamate _ lsoamyl-para-methoxycinnamate Ethyihexyl methoxycinnamate Empirical formula: Empirical formula: C151-12003 C 8H26O3 Chemical names: Cinnamates Chemical names: Amyl4-methoxycinnamate; isopentyl-4- 2-Ethylhexyl-4-methoxycin nam ate; methoxycinnamate; isopenlyl-para- Cinoxate 2-ethyl-hexyl-para-methoxycinnamate; methoxy-cinnamate; 3-(4-methoxyphenyl)- Empirical formula: para-methoxycinnamic acid, 2-ethylhexyl 2-propenoic acid, isopentyl ester Ci4HieO4 ester; 3-(4-methoxyphenyl)-2-propenoic acid, 2-ethylhexyl ester; octinoxate; octyl Trade names: Chemical names: methoxycinnamate; 2-propenoic acid, 3- Neo Heliopan type E 1000; Solarum AMC 2- Ethoxyothyl-para-methoxyci n nam ate; (4-methoxyphenyl)-2-ethylhexyl ester 2-propenoic acid, 3-(4-methoxyphery- para-A minobenzoic acids (PA BAs) 2-ethoxyethyl ester; 2-ethoxyethyl-4- Trade names: methoxycinnamate AEC Octyl Methoxycinnamate; Escalol Amyl dimethyl FABA 557; Eusolex 2292; Heliosol 3; Empirical formula: Trade names: Jeescreen OMC; Katoscreen OMC; Nec C14H21 NO2 Giv Tan F; Phiasol
    [Show full text]
  • WO 2013/036901 A2 14 March 2013 (14.03.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/036901 A2 14 March 2013 (14.03.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 8/30 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US2012/054376 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 10 September 2012 (10.09.2012) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (26) Publication Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (30) Priority Data: ZM, ZW. 61/532,701 9 September 201 1 (09.09.201 1) US (84) Designated States (unless otherwise indicated, for every (71) Applicant (for all designated States except US): UNIVER¬ kind of regional protection available): ARIPO (BW, GH, SITY OF FLORIDA RESEARCH FOUNDATION, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, INC.
    [Show full text]
  • Sun Protection
    [ Oncology Watch] Sun Protection: What We and Our Patients Need to Know To preserve their health and the appearance of their skin, patients need straight- forward, practical advice on susncreen selection and protection strategies. By Jonathan Wolfe, MD rom preventing skin cancer to pre- measures protection against cutaneous burning. Even a FDA public education serving a youthful appearance, burning—the effects of UVB—and does piece states, “A higher number means it Fsunscreens play an important role not account for UVA radiation at all.5 As protects longer.”7 This is not a strictly in dermatologic care. However, some a result, a product with a high SPF could accurate interpretation of the SPF value confusion persists among patients and actually confer little or no protection and ignores the fact that unique proper- even some practitioners when it comes to against UVA. ties of the main sunscreen ingredients SPF, available chemical and physical sun- The somewhat esoteric description of (chemical or physical) and the formula- screens, and the best advice for sun SPF calculation is available online at the tion (waterproof, water resistant) influ- avoidance. In recognition of the AAD’s FDA website.6 Ultimately, the SPF num- ence duration of protection. Skin Cancer Detection and Prevention ber represents the ratio of the MED for Patients also often falsely assume that Month, I’ll review important patient protected skin (MED(PS)) to the MED the increase in SPF value is proportion- education points. for unprotected skin (MED(US)). Tests ate to the increase in UVB protection. It are conducted only in patients with skin is not.
    [Show full text]
  • Sun Protection
    DRUG NEWS Recommending the Best Sun Protection Clinical Pearls: o Recommend a “broad-spectrum” sunscreen – one that covers UVB, UVA1, and UVA2. o Recommend SPF 30-50 o Advise on non-pharmacological sun protection methods o Emphasize proper sunscreen application technique o Emphasize skin protection when taking drugs known to cause photosensitivity. Familiarize yourself with known implicated drugs by referring to appendix 2. Background 1-4 The sun emits 3 types of ultraviolet (UV) radiation: UVC (100-290 nm), UVB (290-320 nm), and UVA (320 -400 nm). UVA rays can be further divided into the shorter UVA2 rays and the longer UVA1 rays. UVC rays, the shortest rays, are completely absorbed by the ozone layer, whereas UVB rays penetrate the epidermis and UVA rays, the longest rays, penetrate into the dermis. The main consequence of UVB irradiation is sunburn, but can also include immunosuppression and skin cancer. Consequences of UVA radiation include: phototoxicity (i.e. involvement in drug-induced sun sensitivity reactions), photo-aging, immunosuppression, and skin cancer. What is SPF? 2,5,6,7 It is easy to be misled by Sun Protection Factors (SPF). SPF is assessed through a standardized test by finding the ratio of the minimal dose of solar radiation that produces perceptible erythema (i.e., minimal erythema dose) on sunscreen-protected skin compared with unprotected skin. Sunburn is caused primarily by UVB rays (and shorter UVA2 rays), and thus SPF indicates mostly UVB protection. However, UVA protection is equally important since it is responsible for photo-aging and cancer. Therefore, it is important to look for the phrase “broad spectrum” when choosing a sunscreen as broad spectrum indicates both UVB and UVA protection.
    [Show full text]
  • Food and Drug Administration, HHS § 352.20
    Food and Drug Administration, HHS § 352.20 (c) Cinoxate up to 3 percent. than 2 to the finished product. The fin- (d) [Reserved] ished product must have a minimum (e) Dioxybenzone up to 3 percent. SPF of not less than the number of (f) Homosalate up to 15 percent. sunscreen active ingredients used in (g) [Reserved] the combination multiplied by 2. (h) Menthyl anthranilate up to 5 per- (2) Two or more sunscreen active in- cent. gredients identified in § 352.10(b), (c), (i) Octocrylene up to 10 percent. (e), (f), (i) through (l), (o), and (q) may (j) Octyl methoxycinnamate up to 7.5 be combined with each other in a single percent. product when used in the concentra- (k) Octyl salicylate up to 5 percent. tions established for each ingredient in (l) Oxybenzone up to 6 percent. § 352.10. The concentration of each ac- (m) Padimate O up to 8 percent. tive ingredient must be sufficient to (n) Phenylbenzimidazole sulfonic contribute a minimum SPF of not less acid up to 4 percent. than 2 to the finished product. The fin- (o) Sulisobenzone up to 10 percent. ished product must have a minimum (p) Titanium dioxide up to 25 percent. SPF of not less than the number of (q) Trolamine salicylate up to 12 per- sunscreen active ingredients used in cent. the combination multiplied by 2. (r) Zinc oxide up to 25 percent. (b) Combinations of sunscreen and skin [64 FR 27687, May 21, 1999] protectant active ingredients. Any single sunscreen active ingredient or any per- EFFECTIVE DATE NOTE: At 67 FR 41823, June mitted combination of sunscreen ac- 20, 2002, § 352.10 was amended by revising tive ingredients when used in the con- paragraphs (f) through (n), effective Sept.
    [Show full text]
  • Four Common Sunscreen Questions – Spring 2015
    Four common sunscreen questions – Spring 2015 Use this information SPF to help you advise 30 your customers about Use the Sun Protection System sunscreen use. 30 SP F 1. How do sunscreens filter the slip, slop, slap, and wrap sun’s rays? Sunscreens may contain physical or chemical Ethoxyethyl p-methoxycinnamate barriers to screen skin against the sun’s (cinoxate)) ultraviolet radiation (UV radiation). While physical barriers reflect or scatter the UV rays, » Salicylates (Homomenthyl salicylate chemical barriers act by absorbing the UV (homosalate), Ethylhexyl salicylate (octyl radiation before it hits the skin. salicylate/octisalate), Trolamine salicylate General advice is to choose a sunscreen which » Avobenzone (butyl methoxydibenzoylmethane) is broad spectrum, which means it filters both UVA and UVB rays. Those who have sensitive » Ecamsule ((terephthalylidene dicamphor skin should choose a sunscreen labelled sulfonic acid; Mexoryl SX) hypoallergenic or low irritant. » Ensulizole ((phenylbenzimidazole sulfonic Typical chemical absorbers include: acid) » Aminobenzoic acid derivatives (Glyceryl » Bemotrizinol (Tinosorb S) PABA), Padimate O, Roxadimate) » Bisoctrizole (Tinosorb M) » (Dioxybenzone, Benzophenones Physical blockers are titanium dioxide and Oxybenzone, Sulisonbenzone) zinc oxide. When applied they leave a thick » Cinnamates (Octocrylene, Octyl opaque (white) layer on the skin. Microfine or methoxycinnamate (octinoxate), nanoparticles of both are transparent on the skin and reflect UV radiation. 2. Do babies’ need a special sunscreen? » Babies’ skin is very sensitive and can sunburn easily so keep them out of the sun. » Once a baby is moving use the sun protection system. » Patch test an untried sunscreen on the skin 24 hours before applying it widely to check that there is no reaction.
    [Show full text]
  • Foolproof Tips for Staying Safe in The
    Summer Sun eFoolproofssentials Tips for Staying Safe in the Sun Happy summer! It’s finally summer! That means cookouts, beach vacations, and relaxing by the pool. Not many people will argue that there’s a better way to celebrate the summer season than by spending more time outdoors and enjoying some sunshine. However, with the summer season comes some responsibility to take care of yourself – especially your skin. Too much time in the sun can lead to wrinkles, premature aging, and even skin cancer. While sunburns might not seem like a big deal, they can do a lot of damage in a short amount of time. On average, about half of the U.S. population experiences a sunburn at least once a year. This means that many Americans aren’t practicing essential sun safety rules. Skin cancer is the most common form of cancer in the United States. It’s estimated that nearly 9,500 people in the U.S. are diagnosed with it every day, according to the American Academy of Dermatology. And according to the Skin Cancer Foundation, one in five Americans will develop skin cancer by the age of 70. These statistics show that many Americans aren’t doing enough to protect their skin and their overall health. We created this sun safety guide to educate you about the importance of sun protection, as well as share some tips on how to have a safe summer. In this guide you’ll learn: • Best practices for sun safety • How to choose the best sunscreen • Common risk factors for skin cancer • Tips for skin cancer prevention Plus, we also included a printable tip sheet for employers to pass around the office to help educate their employees on the importance of sun safety.
    [Show full text]
  • Sunscreen: the Burning Facts
    United States Air and Radiation EPA 430-F-06-013 Environmental Protection (6205J) September 2006 1EPA Agency Sun The Burning Facts Although the sun is necessary for life, too much sun exposure can lead to adverse health effects, including skin cancer. More than 1 million people in the United States are diagnosed with skin cancer each year, making it the most common form of cancer in the country, but screen: it is largely preventable through a broad sun protection program. It is estimated that 90 percent of non- melanoma skin cancers and 65 percent of melanoma skin cancers are associated with exposure to ultraviolet 1 (UV) radiation from the sun. By themselves, sunscreens might not be effective in pro­ tecting you from the most dangerous forms of skin can- cer. However, sunscreen use is an important part of your sun protection program. Used properly, certain sun­ screens help protect human skin from some of the sun’s damaging UV radiation. But according to recent surveys, most people are confused about the proper use and 2 effectiveness of sunscreens. The purpose of this fact sheet is to educate you about sunscreens and other important sun protection measures so that you can pro­ tect yourself from the sun’s damaging rays. 2Recycled/Recyclable—Printed with Vegetable Oil Based Inks on 100% Postconsumer, Process Chlorine Free Recycled Paper How Does UV Radiation Affect My Skin? What Are the Risks? UVradiation, a known carcinogen, can have a number of harmful effects on the skin. The two types of UV radiation that can affect the skin—UVA and UVB—have both been linked to skin cancer and a weakening of the immune system.
    [Show full text]
  • Almost Summer Sun Protection Edition: Sunscreen 2019, Sunscreen Danger?, UPF Clothing
    © Take 3 – Practical Practice Pointers June 3, 2019 Edition Almost Summer Sun Protection Edition: Sunscreen 2019, Sunscreen Danger?, UPF Clothing From the Consumer Reports and Caveat Emptor 2019 1) Sunscreen 2019: Not All Sunscreens Deliver Claimed SPF Ultraviolet radiation (UV) exposure is recognized as a major environmental risk factor for both melanoma and keratinocyte cancers. The sun protection factor (SPF) is a relative measure of how long a sunscreen will protect you from UVB rays, which are the chief cause of sunburn and a contributor to skin cancer. Usually the number is explained as the amount of time it takes an individual’s skin to burn when it’s covered in sunscreen compared with when it’s not. For example, assuming you apply—and reapply—the sunscreen correctly, if you’d normally burn after 20 minutes in the sun an SPF 30 protects for about 10 hours. SPF calculations do not apply to UVA rays, which can tan and age skin and also trigger skin cancer. Thus the need for a broad-spectrum sunscreen that provides protection against both types of UV rays. However, no sunscreen blocks 100 percent of UVA or UVB rays. The breakdown: SPF 30 blocks 97 percent of UVB rays, SPF 50 blocks 98 percent, and SPF 100 blocks 99 percent. The Consumer Reports organization yearly tests sunscreens to see how close they approximate their claims. In 2019, of the 82 lotions, sprays, sticks, and lip balms tested, 32 tested at less than half their labeled SPF number. These results aren’t a fluke. Similar patterns have been found in previous years’ sunscreen tests.
    [Show full text]
  • Federal Register/Vol. 84, No. 38/Tuesday, February 26, 2019
    6204 Federal Register / Vol. 84, No. 38 / Tuesday, February 26, 2019 / Proposed Rules DEPARTMENT OF HEALTH AND the public. Similarly, if your submission 1978–N–0018 (formerly Docket No. HUMAN SERVICES includes safety and effectiveness data or FDA–1978–N–0038) for ‘‘Sunscreen information marked as confidential by a Drug Products for Over-the-Counter Food and Drug Administration third party (such as a contract research Human Use.’’ Received comments, those organization or consultant), you should filed in a timely manner (see 21 CFR Parts 201, 310, 347, and 352 either include a statement that you are ADDRESSES), will be placed in the docket [Docket No. FDA–1978–N–0018] (Formerly authorized to make the information and, except for those submitted as Docket No. FDA–1978–N–0038) publicly available or include an ‘‘Confidential Submissions,’’ publicly authorization from the third party viewable at https://www.regulations.gov RIN 0910–AF43 permitting the information to be or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday Sunscreen Drug Products for Over-the- publicly disclosed. If you submit data through Friday. Counter Human Use without confidential markings in response to this document and such • Confidential Submissions—To AGENCY: Food and Drug Administration, data includes studies or other submit a comment with confidential HHS. information that were previously information that you do not wish to be made publicly available, submit your ACTION: Proposed rule. submitted confidentially (e.g., as part of a new drug application), FDA intends to comments only as a written/paper SUMMARY: The Food and Drug presume that you intend to make such submission.
    [Show full text]
  • A Guide to United States Cosmetic Products Compliance Requirements
    NISTIR 8178 A Guide to United States Cosmetic Products Compliance Requirements NISTIR 8178 A Guide to United States Cosmetic Products Compliance Requirements Lisa Benson Karen Reczek This publication is available free of charge from: https://doi.org/10.6028/NIST.IR.8178 NISTIR 8178 A Guide to United States Cosmetic Products Compliance Requirements Lisa M. Benson* Karen Reczek Standards Coordination Office * Dakota Consulting This publication is available free of charge from: https://doi.org/10.6028/NIST.IR.8178 May 2017 Includes updates as of May 31, 2017; see Appendix A U.S. Department of Commerce Wilbur L. Ross, Jr., Secretary National Institute of Standards and Technology Kent Rochford, Acting NIST Director and Under Secretary of Commerce for Standards and Technology Acknowledgements The lead authors for this document Karen Reczek, NIST, and Lisa M. Benson, Dakota Consulting, under contract to the Standards Coordination Office of NIST. Additional guidance, initial research, and review of the document were provided by the staff of the Standards Coordination Office of NIST including: Mary Donaldson and Erik Puskar. Invaluable support was also received from the knowledgeable experts of the Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Food and Drug Administration (FDA), Federal Trade Commission (FTC), International Cosmetics Manufacturers and Distributors Association (ICMAD), International Trade Administration (ITA), the Personal Care Products Council (PCPC), This publication is available free of charge from: ht and UL, Inc. who provided input into the document and conducted a thorough review. From the CPSC: Mary Boyle, Patricia Pollitzer, and Mary Toro; From the EPA: Keith Mason and Alexander Metcalf; From the FDA: Jeffrey Read, Linda Katz, and Tracy DuVernoy; From the FTC: Stephen C.
    [Show full text]